Statistics from Altmetric.com
We read the article by Vizzutti et al (Gut 2009;58:157–60) with great interest; however, we are uncertain that the proposed algorithm for the non-invasive assessment of fibrosis evolution in patients with chronic hepatitis C (CHC) infection is the best way to utilise the information provided by transient elastography (TE).
The role of non-invasive tests for liver fibrosis is still evolving. Historically, liver biopsy was used to target treatment for patients only with moderate to advanced fibrosis (METAVIR ⩾F2). In the United Kingdom, liver biopsy has not been a requirement to guide antiviral therapy since 2006.1 Therefore, irrespective of fibrosis stage, patients with CHC, and without contra-indications, can …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.